Phase 1 Study of Allogeneic CD30.CAR-EBVSTs in Relapsed/Refractory Lymphomas
A clinical trial is investigating the safety and efficacy of allogeneic CD30.CAR-EBVSTs in patients with relapsed or refractory CD30-positive lymphomas.
Company
Pharmaceutical intelligence for CD30.CAR-EBVSTs with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.